 | |  | |  | |  | |  | |  | |  | |  |
| IJCEM Copyright © 2008-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711 |
Int J Clin Exp Med 2010; 3(3):245-247
Brief Communication
Dutasteride prevents the growth response to testosterone in androgen-sensitive
benign and malignant prostate cells
Joseph M. Alisky, Yaqiong Tang, Gabriel K. Habermehl, Kenneth A. Iczkowski
Total Longterm Care, 3551 North Chambers Boulevard, Aurora, Colorado, USA; Department of Pathology, University of Colorado Health
Science Center, Aurora, Colorado, USA.
Received June 22, 2010, accepted June, 2010, available online June, 2010
Abstract: We show that the dual 5-α reductase enzyme inhibitor dutasteride prevents enhanced growth of both benign and malignant
prostate cell lines, incubated with physiologic to supraphysiologic doses of testosterone. Using androgen-sensitive benign BPH-1
cells, LNCaP cancer cells, their derivative C4-2 cells, or Dunning rat cancer cells, we subjected 30,000 cells/well to concomitant
treatment with 10-9, 10-8, or 10-7 M testosterone in the presence of low (0.25 μM) or high (1.0 μM) doses of dutasteride. Both low- and
high-dose dutasteride abrogated testosterone-stimulated growth of all 4 cell lines. If the in vitro data mimic conditions in men
undergoing testosterone replacement, concomitant dutasteride use might make testosterone safe for men with benign prostatic
hypertrophy, latent prostate cancer and perhaps even aggressive prostate cancer. Testosterone might also be used to prevent the rare
anti-androgen side effects of dutasteride when used for benign prostatic hypertrophy and baldness. Further clinical investigation is
indicated. (IJCEM1006002).
Key words: Prostate cancer, BPH, testosterone, dutasteride
Full Text PDF
Address all correspondence to:
Kenneth A. Iczkowski, MD
Pathology—P.O. Box 6511
UCHSC—Campus Mail Stop 8104
Aurora, CO 80010, USA.
Tel: 303-724-0155, Fax: 303-724-3712
E-mail: Kenneth.Iczkowski@UCDenver.edu
Brief Communication
Dutasteride prevents the growth response to testosterone in androgen-sensitive
benign and malignant prostate cells
Joseph M. Alisky, Yaqiong Tang, Gabriel K. Habermehl, Kenneth A. Iczkowski
Total Longterm Care, 3551 North Chambers Boulevard, Aurora, Colorado, USA; Department of Pathology, University of Colorado Health
Science Center, Aurora, Colorado, USA.
Received June 22, 2010, accepted June, 2010, available online June, 2010
Abstract: We show that the dual 5-α reductase enzyme inhibitor dutasteride prevents enhanced growth of both benign and malignant
prostate cell lines, incubated with physiologic to supraphysiologic doses of testosterone. Using androgen-sensitive benign BPH-1
cells, LNCaP cancer cells, their derivative C4-2 cells, or Dunning rat cancer cells, we subjected 30,000 cells/well to concomitant
treatment with 10-9, 10-8, or 10-7 M testosterone in the presence of low (0.25 μM) or high (1.0 μM) doses of dutasteride. Both low- and
high-dose dutasteride abrogated testosterone-stimulated growth of all 4 cell lines. If the in vitro data mimic conditions in men
undergoing testosterone replacement, concomitant dutasteride use might make testosterone safe for men with benign prostatic
hypertrophy, latent prostate cancer and perhaps even aggressive prostate cancer. Testosterone might also be used to prevent the rare
anti-androgen side effects of dutasteride when used for benign prostatic hypertrophy and baldness. Further clinical investigation is
indicated. (IJCEM1006002).
Key words: Prostate cancer, BPH, testosterone, dutasteride
Full Text PDF
Address all correspondence to:
Kenneth A. Iczkowski, MD
Pathology—P.O. Box 6511
UCHSC—Campus Mail Stop 8104
Aurora, CO 80010, USA.
Tel: 303-724-0155, Fax: 303-724-3712
E-mail: Kenneth.Iczkowski@UCDenver.edu
